Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 18, 2025Breast Cancer ResearchOpen Access

Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

RPRuchi P. PatelEWElizabeth WeilSBSara Bugamelli

Discussion

Loading...

Member takes

Overview

Observational analysis found 20% of patients with incomplete ovarian function suppression, indicating a need for E2 level monitoring.

Key Points

  • Complete ovarian function suppression was achieved in 62.4% of patients, while 20% experienced incomplete suppression.
  • Seventeen percent of patients had elevated E2 levels, prompting changes in GnRH agonist therapy for improvement.
  • A retrospective analysis reviewed the E2 monitoring protocol's effectiveness across 85 patients over 18 months.
  • Findings suggest checking E2 levels might help identify incomplete ovarian function suppression among breast cancer patients.

Cite This Study

Patel et al. (2025) studied this question.

synapsesocial.com/papers/68af2d89cf1dd9ea359e5ec5https://doi.org/10.1186/s13058-025-01979-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Monitoring serum estradiol in premenopausal women with hormone receptor-positive breast cancer on adjuvant LHRH agonists2025
  2. 2Self-Reported Outcomes of Endocrine Therapy with or Without Ovarian Suppression in Premenopausal Breast Cancer Patients: A Brazilian Quality-of-Life Prospective Cohort2025
  3. 3Impact of ovarian function suppression on prognosis in premenopausal patients with HR+/HER2 + early-stage breast cancer: a multi-center retrospective study2025
  4. 4Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study2025
  5. 5The Effect of Hormonal Status on the Results of Aromatase Inhibitor Maintenance Following Adjuvant Chemotherapy for High-Grade Serous Ovarian Cancer (HGSOC)2023